Issues

The cover image was adapted from Figure 3 in the article in this issue, “Repurposing EGFR inhibitor utility in colorectal cancer in mutant APC and TP53 subpopulations,” by Yang and colleagues. The findings of the study suggest that the APC and TP53 combination mutation may account for the laterality of EGFRi sensitivity and provide a rationale for refining treated populations, and also that the addition of APC+TP53 sequencing to extended RAS/RAF testing may directly increase the response rates of EGFRi therapy in selected patients. The original figure is a diagram of the CTX-S scores (high to low) vs. 7 MUT/WT APC/TP53/RAS(KRAS/NRAS)/BRAF subgroups in MSI and MSS tumors displayed for the Moffitt (n = 464) dataset. For more information, see the article beginning on page 1141.